reports
- Hilde Van Boxstael
- Jacob Mekhael
- Michiel Declercq
- Wim Lewi
- Hilde Van Boxstael
- Thomas Couvreur
- Thomas Vranken
- Thomas Vranken
Hyloris FIRST LOOK: Pipeline extends into veterinary medicine
Hyloris adds a new asset to the pipeline that is geared toward veterinary medicine. HY-095 is long-acting injectable formulation of a well-known proton pump inhibitor for the treatment of equine gastric ulcer syndrome, allowing more reliable drug delivery and lower dosing frequency vs. existing orals. Together with its partner, Hyloris will fund development costs and manage clinical trials in exchange for a 90%/10% profit sharing. We reiterate our € 5 TP and Hold rating.
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Lewi
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
Hyloris Governance overhang weighs down the case
Following the FSMA statements and outcome of the independent forensic investigation of the QliniQ transactions, Hyloris will initiate a transition process to a new CEO, and the CFO and CLO will step down. Last week, the stock resumed trading (-75% intraday) following publication of the 2023 annual report, which included a qualified opinion regarding the Pleco agreement. Additionally, the QliniQ transactions case has been referred to the public prosecutor's office. We took a step back to evaluate...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Inventiva Uneventful preliminary 1H24 results, NATiV3 LPFV in 2H24
Inventiva reported uneventful preliminary 1H24 results. The next important milestone for the company is the last patient first visit (LPFV) in the phase 3 (NATiV3) trial of lanifibranor, for which the timeline guidance remains at 2H24 – this event would provide timeline certainty, pinning the timeline for the topline readout to early 2H26. Inventiva's cash runway was extended through September 2024 (previously early 3Q24) by the previously reported royalty certificates of approx. € 20m, which in...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Sharad Kumar S.P
- Thibault Leneeuw
- Thomas Couvreur
- Thomas Vranken
- Wim Hoste
- Wim Lewi
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
Inventiva Reports Preliminary 2024 First-Half Financial Information¹ Cash and cash equivalents at €10.1 million as of June 30, 2024, compared to cash and cash equivalents at €26.9 million, €0.012 million of short-term deposits and €9.03 million of long-term deposits as of December 31, 2023.On July 18, 2024, Inventiva issued royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng) for an amount of approximately €20.1 million.No Revenues recorded in H1 2024, compared to €1.9 million for the same period in 2023. Daix (France...
- Hilde Van Boxstael
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Inventiva secures a new patent in Japan, expanding the IP protection o...
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor Japanese Patent Office approved Inventiva’s patent application relating to the use of lanifibranor for the treatment of cirrhosis.1This patent strengthens Inventiva’s intellectual property with respect to lanifibranor in Japan for the indication cirrhosis, including cirrhosis due to MASH/NASH. Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutica...
Inventiva obtient un nouveau brevet au Japon, élargissant la protectio...
Inventiva obtient un nouveau brevet au Japon, élargissant la protection de la propriété intellectuelle de lanifibranor ► L'Office des brevets japonais a accordé la demande de brevet d'Inventiva concernant l'utilisation de lanifibranor pour le traitement de la cirrhose1. ► Ce brevet renforce la propriété intellectuelle d’Inventiva concernant lanifibranor dans l’indication cirrhose, y compris la cirrhose due à la MASH/NASH. Daix (France), Long Island City (New York, États-Unis), le 25 juillet 2024 – Inventiva (Euronext Paris et Nasdaq: IVA) (« Inventiva » ou la « Société »), société biop...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvre...
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract wit...
Bilan semestriel du contrat de liquidité de la société Inventiva concl...
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux Daix (France), Long Island City (New York, Etats-Unis), le 19 juillet 2024 – Inventiva (Euronext Paris et Nasdaq: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement des patients atteints de stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), également connue sous le nom de stéatohépatite non alcoolique (« NASH »), et d’autres maladies avec un besoin médic...
- Jacob Mekhael
Inventiva €20m in royalty certificates extend runway through September...
Inventiva announced the issuance of €20.1m in royalty certificates in return for a 3% royalty on lanifibranor sales in the US, EU and UK subscribed by Samsara BioCapital, and existing investors BVF Partners, NEA, Sofinnova, and Yiheng. This extends the company's runway through September 2024 (previously early 3Q24), providing Inventiva with breathing room over the summer to work towards completion of recruitment in the phase 3 (NATiV3) trial of lead asset lanifibranor in NASH/MASH (last patient ...
- Hilde Van Boxstael
- Jacob Mekhael
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
Inventiva annonce l'émission de certificats de royalties pour un monta...
Inventiva annonce l'émission de certificats de royalties pour un montant de 20,1 millions d'euros Certificats de royalties souscrits par Samsara BioCapital et des actionnaires existants BVF Partners, NEA, Sofinnova et Yiheng.Royalties de 3 % sur les ventes nettes futures du lanifibranor aux Etats Unis, dans l’Union européenne et au Royaume Uni, sur une période de 14 ans.Position de trésorerie étendue jusqu'à fin septembre 2024 et poursuite de l’évaluation des options stratégiques et financières1. Daix (France), Long Island City (New York, États-Unis), le 18 juillet 2024 – Inventi...
- Jacob Mekhael
Hyloris FIRST LOOK: Management step down after conclusion of forensic ...
Hyloris provided an update following completion of the independent forensic investigation with respect to the QliniQ transactions. While management dispute the findings of the independent forensic review, they have proposed to step down from their roles in the interest of the company. In addition, we welcome the board's decision to strengthen Hyloris' governance, which in our view will contribute to building investor trust going forward. This aside, we continue to believe in the business case, a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.